Skip to content
10-Q

Quarterly Report

SKINOVATION PHARMACEUTICAL INCORPORATED

0001554795-23-000334

← back to feed
Filed
Nov 2, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 2, 2023 708K sh
Cash And Equivalents Q3 2023 · Sep 30, 2023 $9.63K
Cash And Equivalents Q3 2023 · Dec 31, 2022 $163
Current Liabilities Q3 2023 · Sep 30, 2023 $447.88K
Current Liabilities Q3 2023 · Dec 31, 2022 $411.5K
Total Liabilities Q3 2023 · Sep 30, 2023 $447.88K
Total Liabilities Q3 2023 · Dec 31, 2022 $411.5K
Current Assets Q3 2023 · Sep 30, 2023 $9.63K
Current Assets Q3 2023 · Dec 31, 2022 $163
Total Assets Q3 2023 · Sep 30, 2023 $9.63K
Total Assets Q3 2023 · Dec 31, 2022 $163
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$7.75K
Stockholders Equity Q3 2023 · Sep 30, 2022 −$403.55K
Stockholders Equity Q3 2023 · Jun 30, 2022 −$395.82K
Stockholders Equity Q3 2023 · Mar 31, 2022 −$388.04K
Stockholders Equity Q3 2023 · Dec 31, 2021 −$377.59K
Sga Expense Q3 2023 · Sep 30, 2022 $2.76K
Sga Expense Q3 2023 · Sep 30, 2022 $11.25K
Net Income Q3 2023 · Sep 30, 2022 −$7.73K
Net Income Q3 2023 · Sep 30, 2022 −$25.95K
Net Income Q3 2023 · Jun 30, 2022 −$7.78K
Net Income Q3 2023 · Mar 31, 2022 −$10.45K
Operating Income Q3 2023 · Sep 30, 2022 −$2.76K
Operating Income Q3 2023 · Sep 30, 2022 −$11.25K